Azitromicina Nifa

Quick links

Choose a section

Quick links to important sections

Advertisements

Azitromicina Nifa

Advertisements

Overview of Azitromicina Nifa

This section provides a factual definition and classification of the medicine Azitromicina Nifa, detailing its composition and general function, strictly excluding information on dosage, specific diseases, or safety.

Property Description
Active ingredient Azithromycin
Form Tablets, Oral Suspension, Powder for Infusion
Pharmacological class Macrolide Antibiotic (Azalide subclass)
General purpose To inhibit the growth of susceptible bacterial pathogens
Origin Semi-synthetic

What Type of Medicine is Azitromicina Nifa?

Azitromicina Nifa is a prescription-only medicine containing the active substance Azithromycin (INN), which is utilized to combat infections caused by susceptible bacteria. The medicine is categorized as a macrolide antibiotic and belongs specifically to the Azalide subclass of antimicrobial agents. This classification establishes the medicine's role as an agent targeting bacteria.

Structurally, Azithromycin is a semi-synthetic compound, derived from the older antibiotic Erythromycin through a chemical modification. This modification results in improved stability and prolonged presence in body tissues. Its general purpose is to provide a reliable, broad-spectrum defense against bacterial pathogens.


Composition and Available Forms

The therapeutic effectiveness of Azitromicina Nifa relies on its single active ingredient, Azithromycin, and is not a combination product. This medicine is manufactured in several high-level dosage forms to accommodate various patient needs and routes of administration. These forms commonly include film-coated tablets for easy oral use, oral suspension (liquid) which is often used for pediatric patients, and powder for solution for infusion for intravenous (IV) administration. This availability ensures clinical flexibility in treatment initiation and progression.


Azitromicina Nifa: General Purpose and Mechanism Summary

The core objective of this medicine is to halt the progression of a bacterial illness. Azithromycin achieves this by interfering with the bacteria’s ability to produce essential proteins necessary for their growth and survival. This function classifies it as a Protein Synthesis Inhibitor. This mechanism means the drug provides a systemic method to control the bacterial load, thereby facilitating the body's natural defense against the infection.

Advertisements

What side effects are possible with Azitromicina Nifa?

Official Adverse Reactions and Safety Profile

The safety characteristics of Azithromycin, the active ingredient in Azitromicina Nifa, are documented by regulatory authorities (e.g., EMA, FDA) and classified by the System Organ Class (SOC) and observed frequency.

Adverse reactions are most frequently reported in the gastrointestinal system. Officially classified as Very Common (ge 1/10 people) are diarrhoea, abdominal pain, nausea, and flatulence. Common reactions (less than 1 in 10) include headache, dizziness, vomiting, and rash.


Serious Adverse Reactions

The regulatory safety profile highlights the potential for several serious adverse reactions. These include the risk of QT interval prolongation (a change in the heart's electrical activity), which is associated with the risk of developing a serious type of irregular heart rhythm. Documented serious events also involve the liver, with reports of severe hepatotoxicity, including cases of fulminant hepatitis and hepatic failure.

Severe hypersensitivity reactions (allergic reactions), such as anaphylaxis, angioedema, and serious skin conditions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are officially classified as potential risks.


Population-Specific Constraints

Specific regulatory cautions apply to certain populations. Use requires particular care in individuals with severe hepatic or renal impairment. Older adults may have an increased susceptibility to the documented cardiac risks. Furthermore, the label notes reports of Infantile Hypertrophic Pyloric Stenosis (IHPS) following use in neonates (treatment up to 42 days of life).

Advertisements

Overdose and Emergency Response

Azitromicina Nifa Overdose and when to seek help: Official Regulatory Information

The official prescribing information for Azithromycin establishes distinct manifestations and required emergency actions in the event of overdosage.

Domain Documented Manifestations and Actions
Documented Presentations Overdosage may present with severe gastrointestinal symptoms that are similar to those reported at high therapeutic doses, primarily including pronounced nausea, vomiting, and diarrhea, as stated in regulatory documents. Additionally, hearing disturbances such as tinnitus or temporary hearing loss have also been reported in the overdose context.
Life-Threatening Outcomes The critical, life-threatening risk involves the cardiovascular system, specifically the documented potential for Prolongation of the QT Interval. This electrical abnormality can escalate to potentially fatal arrhythmias, such as Torsades de pointes, and is associated with a risk of cardiovascular death. Rare cases of severe hepatic necrosis and hepatic failure have also been documented as serious outcomes.
Mandated Emergency Action Immediate medical care must be sought if specific symptoms occur, including an irregular heartbeat, shortness of breath, dizziness, or fainting. Individuals should contact emergency services immediately if they are unable to be awakened, have collapsed, or are experiencing a seizure, as required by official guidance.
Management Protocol No specific antidote is known for Azithromycin overdosage. Management is strictly limited to administering general symptomatic and supportive measures as required by regulatory authorities, and the use of medicinal charcoal may be indicated. The need for cardiac monitoring is implied by the potential for life-threatening arrhythmias.
Population Considerations The prescribing information contains specific warnings regarding infants where accidental intravenous overdose has been documented to cause severe cardiotoxicity, including severe heart block and subsequent residual encephalopathy.
Advertisements

Therapeutic Uses of Azitromicina Nifa

Azitromicina Nifa is generally used as a macrolide antibiotic to help manage a wide range of infections caused by susceptible bacteria. Its therapeutic application is relevant in contexts involving heightened systemic burden, and is applied across therapeutic domains involving certain distressing symptoms.

The medicine is commonly used across conditions presenting with acute episodes of infection. This includes conditions associated with acute or disruptive episodes, such as pneumonia and acute exacerbations of bronchitis, as well as localized problems like bacterial pharyngitis, uncomplicated skin infections, and acute middle ear infections. It is also considered relevant for certain sexually transmitted bacterial infections.

Symptom Relief and Therapeutic Benefits

Azitromicina Nifa is applied in clinical settings that involve acute or unstable symptom patterns, helping address symptom clusters that may become intense or disruptive, such as pronounced cough, fever, and localized pain. In situations where patients experience these manifestations, it contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable. This is particularly helpful when patients experience intense symptoms like ear pain (otalgia) or painful urination (dysuria).

“The primary goal is to provide supportive relief during difficult episodes, assisting with maintaining functional stability.”


Quick Fact: Relief for Inflammatory Symptoms

Quick Fact: Relief for Inflammatory Symptoms Azitromicina Nifa may assist with managing symptoms related to inflammatory or irritative states, contributing to improved comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Azitromicina Nifa eligibility is strictly determined by official regulatory guidelines, which define populations who must not use the medicine and those for whom use is restricted or conditional.

Populations Who Must Not Use (Contraindicated)

The medicine is formally contraindicated for patients with a known hypersensitivity or allergic reaction to azithromycin itself, any macrolide, or any ketolide antibiotic. Use is also prohibited if the patient has a history of cholestatic jaundice or hepatic dysfunction specifically linked to a prior course of azithromycin.

Special Populations and Conditions

The medicine requires special consideration in several patient groups, as defined by regulators:

  • Pediatric Use: Safety and effectiveness are not established for most infections in infants under 6 months of age. The label also notes a reported risk of Infantile Hypertrophic Pyloric Stenosis (IHPS) in neonates (treatment up to 42 days of life).
  • Organ Function: Caution is advised in patients with severe renal impairment (GFR <10 mL/min) or impaired hepatic function. Use is generally not recommended in those with severe liver disease.
  • Cardiac Risk: Patients with pre-existing proarrhythmic conditions, such as known QT prolongation, uncorrected low potassium/magnesium, or clinically significant bradycardia, must be assessed carefully due to the risk of cardiac arrhythmia.
  • Other Conditions: The medicine may exacerbate muscle weakness in individuals with myasthenia gravis.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Azitromicina Nifa (azithromycin) has documented interactions with several categories of medicinal products, necessitating specific clinical management based on regulatory guidance.

Interacting Product Category Regulatory Constraint/Requirement
QT-Prolonging Agents (e.g., Pimozide, Class IA/III Antiarrhythmics, Cisapride) Use is highly restricted or avoided due to an increased risk of QTc prolongation and Torsades de Pointes.
Ergot Derivatives (e.g., Ergotamine) Avoid co-administration due to the theoretical potential for ergotism, a serious complication documented with other macrolides.
Coumarin-Type Oral Anticoagulants (e.g., Warfarin) Requires frequent monitoring of prothrombin time, as post-marketing reports have indicated a potential for potentiated anticoagulation.
P-glycoprotein Substrates (e.g., Digoxin) Requires careful monitoring of the substrate's serum concentration, as Azithromicina Nifa may increase levels of P-glycoprotein-sensitive drugs.
Antacids (containing aluminum or magnesium hydroxide) Requires time separation between administration of the two products, as Antacids significantly reduce the peak plasma concentration of Azithromicina Nifa.
Nelfinavir (HIV Protease Inhibitor) Requires close monitoring for known adverse reactions to Azithromicina Nifa, as Nelfinavir is documented to increase the concentration of azithromycin in the blood.

These interactions are formally classified in regulatory documents based on the mechanistic basis, which includes pharmacodynamic effects (like additive QT prolongation) and pharmacokinetic effects (like altered absorption or P-glycoprotein interaction). This structure defines the mandatory restrictions for simultaneous use.

Advertisements

Mechanism of Action

The mechanism of action for Azitromicina Nifa (Azithromycin) is two-fold, involving a primary effect against the bacterial target and a secondary influence on the host's immune system.


Targeted Inhibition of Microbial Protein Synthesis

Azithromycin acts as an inhibitor by physically blocking the peptide exit tunnel on the bacterial 70S ribosome, specifically within the 50S ribosomal subunit. This interaction prevents the essential translocation step of protein elongation. This molecular interference fundamentally halts the growth and replication of susceptible bacteria, leading to systemic reduction of the viable bacterial load.


Modulation of Host Inflammatory Signals

Beyond its direct antimicrobial role, Azithromycin acts as a modulator of immune function within host tissues. It affects cellular signaling by downregulating the release of various pro-inflammatory cytokines and reducing the migration of certain immune cells to the site of stress. This action results in the modulation of inflammatory cascade activity within the affected tissues.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Azitromicina Nifa (Azithromycin) is used according to specific guidelines for route, frequency, and dosage. The medicine is available for both oral (PO) administration, using tablets or suspension, and intravenous (IV) administration, using powder for infusion.

Dosing Patterns and Frequency

Most adult regimens utilize a once-daily (qDay) administration schedule, reflecting the drug’s long half-life. Standard oral courses are typically prescribed for a total of three or five days. For certain specific infections, a single 1000 mg oral dose is utilized. When initiating treatment with the intravenous form, 500 mg is administered once daily, often preceding a transition to oral therapy to complete a seven to ten-day total course.

Administration Contexts

Oral doses can generally be taken with or without food. However, the medicine must not be taken simultaneously with antacids that contain aluminum or magnesium; it is recommended to separate the two by at least one to two hours. For the intravenous form, the powder must be reconstituted and further diluted before being infused slowly over a period of at least one hour; it is strictly forbidden to administer the IV form as a rapid bolus injection.

Population-Specific Use

Dosage for pediatric patients is calculated based on body weight (mg/kg). For adults, no dose adjustment is required for those with mild to moderate renal or hepatic impairment. If an oral dose is missed, it should be taken immediately, and the regular schedule resumed the next day, strictly avoiding the administration of two doses at once.

Advertisements

Recent Clinical Evidence

The research base for Azitromicina Nifa (Azithromycin) relies on short-term Randomized Controlled Trials (RCTs) and observational studies that evaluate its use for acute conditions like Community-Acquired Pneumonia (CAP), Acute Otitis Media (AOM), and certain Sexually Transmitted Bacterial Infections (STIs). Studies in these areas typically monitor outcomes such as all-cause mortality, hospitalization metrics, and measured endpoints like clinical resolution status over short intervals.

For chronic conditions, such as Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis, evidence comes from Placebo-Controlled RCTs exploring intermediate to long-term use. Researchers examined the frequency of acute exacerbations and monitored Quality of Life (QoL) scores. These long-term studies also tracked potential physiological changes, including metrics related to hearing impairment and specific cardiac measurements (QTc prolongation).

A critical area of uncertainty across the research is the development and spread of macrolide-resistant bacteria, which multiple studies have shown an association with prolonged use. The long-term effects on the cardiovascular and auditory systems are not fully established beyond the periods covered by the main controlled trials. Furthermore, the evidence quality varies, with studies like the Mass Drug Administration (MDA) trials for child survival describing significant inconsistency in results across different settings. Data for patients with certain comorbidities, particularly severe heart conditions, remain insufficient as these groups were often excluded from initial trials.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Azitromicina Nifa (FAQ)

Q: What happens if I miss a dose of Azitromicina Nifa?

If an oral dose is forgotten, official regulatory information advises taking it immediately when remembered. The guidance is to resume the regular schedule the following day, strictly avoiding the administration of two doses at once to compensate for the missed one.


Q: Does Azitromicina Nifa affect the gut flora (good bacteria)?

As an antibiotic, Azitromicina Nifa works by inhibiting bacterial growth, which can sometimes disturb the body's natural microbial balance, including the gut flora. Regulatory adverse reaction reports include gastrointestinal issues and Clostridium difficile-associated diarrhea, which are known effects related to this disruption.


Q: Is Azitromicina Nifa often prescribed for skin infections?

Official indications for Azithromycin include the treatment of certain uncomplicated skin and skin structure infections caused by susceptible bacteria. Regulatory documents indicate that the medicine is used for these infections when caused by susceptible bacteria.


Q: Can I take Azitromicina Nifa if I am allergic to other antibiotics?

According to official documentation, Azitromicina Nifa is contraindicated (should not be used) if a person has a known hypersensitivity (allergic reaction) to azithromycin, erythromycin, or any macrolide or ketolide antibiotic. This restriction is in place due to the risk of cross-reactivity with drugs in the same class.


Q: Can children take Azitromicina Nifa?

Yes, regulatory information includes dosing guidelines for children and adolescents, with dosages typically calculated based on body weight. The safety and effectiveness for infants younger than six months are not established for all indications, and the use in these age groups is subject to official regulatory guidance.


Q: Are there any known issues with taking Azitromicina Nifa during pregnancy?

Official prescribing information states that the medicine should only be used during pregnancy if the potential benefit is determined to justify the potential risk to the fetus. It is known to pass into breast milk in small amounts, and monitoring for effects on the infant is recommended if used while breastfeeding.


Q: How long does Azitromicina Nifa stay in your system after the last dose?

Azithromycin is known to have a long half-life, which is officially reported to be approximately 68 hours. This means the drug remains in the body's tissues for several days after the last dose, which contributes to its effectiveness over a short course.


Q: What official research evidence supports the use of Azitromicina Nifa?

Regulatory documents rely on evidence from controlled clinical trials and other studies that have shown efficacy for its approved indications, such as Community-Acquired Pneumonia and certain sexually transmitted infections. The studies evaluate outcomes like clinical resolution of the infection.


Q: How quickly should I expect to feel better after starting Azitromicina Nifa?

The drug’s effect, which involves inhibiting bacterial growth, begins after the first dose. The time needed for clinical improvement (feeling better) is highly dependent on the type and severity of the infection, and a specific timeline for clinical improvement is not stated in regulatory documents.


Q: Is Azitromicina Nifa the same as regular Azithromycin?

Azitromicina Nifa is a brand name for a product containing the active substance Azithromycin. Regulatory documents confirm that Azithromycin is the pharmacologically active ingredient responsible for treating the infection.


Q: What is the main difference between Azitromicina Nifa and penicillin?

Azitromicina Nifa (Azithromycin) is a macrolide antibiotic that works by stopping bacteria from making necessary proteins. Penicillins are beta-lactam antibiotics that function by disrupting the formation of the bacterial cell wall. They belong to different chemical classes with distinct mechanisms of action.


Q: Can Azitromicina Nifa be used to treat a common cold or flu?

No. Azitromicina Nifa is classified as an antibiotic and is officially indicated only for treating infections caused by susceptible bacteria. Official sources state it is not effective against viral infections, which are the cause of the common cold or flu.


Q: Can Azitromicina Nifa affect the results of blood tests?

Yes, official adverse reaction lists include changes in various blood test parameters. These changes may involve increased liver enzymes, increased blood urea, or alterations in white blood cell counts, which may require monitoring.


Q: Is there a certain time of day that is better for taking Azitromicina Nifa?

Regulatory guidance states the medicine should be taken as a single daily dose, and the tablets or liquid can generally be taken with or without food. Official documents often recommend taking it at the same time each day for consistency, but do not define an optimal time of day.


Q: Can Azitromicina Nifa interact with birth control pills?

Regulatory guidance suggests that Azithromycin does not typically stop oral contraceptives from working effectively. However, if a patient experiences severe vomiting or diarrhea for more than 24 hours while taking the medicine, the contraceptive pill's effectiveness may be reduced.


Q: Is Azitromicina Nifa used for long-term treatment?

While the common course is short (3 or 5 days), Azithromycin is officially indicated in regulatory documents for long-term or intermittent use for the prevention of certain specific infections, such as Disseminated Mycobacterium avium Complex (MAC).


Q: Can drinking alcohol while taking Azitromicina Nifa cause problems?

Official labeling does not list a direct chemical interaction with alcohol. However, alcohol consumption can potentially worsen documented side effects like nausea, vomiting, dizziness, and liver problems, and may also delay recovery from the underlying infection.


Q: Is Azitromicina Nifa an antibiotic or an antiviral?

Azitromicina Nifa is definitively classified as an antibiotic and belongs to the macrolide group. Its mechanism of action targets bacterial structures and it is not used for treating viruses.


Q: Can Azitromicina Nifa affect my ability to drive or operate machinery?

Due to potential adverse effects such as dizziness or visual impairment that have been documented, official documents describe that caution may be warranted when driving or operating machinery.


Q: Are there any specific foods or drinks I must avoid while on Azitromicina Nifa?

Official labeling advises separating the administration of antacids containing aluminum or magnesium hydroxide by at least one to two hours to prevent reduced absorption of the drug. No other specific food or drink is contraindicated.


Q: Does Azitromicina Nifa work immediately after taking the first pill?

The mechanism of action, which involves inhibiting bacterial growth, begins immediately after the medicine is absorbed into the body. The full therapeutic effect is a gradual process, as it takes time to reach effective concentrations at the infection site and reduce the bacterial load.


Q: What should I do if I accidentally take too much Azitromicina Nifa?

Regulatory guidance on overdose states that taking too much may result in enhanced side effects, such as severe nausea, vomiting, and diarrhea. The guidance for an overdose situation is to seek immediate medical attention.


Q: Can Azitromicina Nifa be split or crushed if I have trouble swallowing pills?

The availability of an oral suspension (liquid form) exists for those who have trouble swallowing. Whether a tablet can be split or crushed depends on the specific product formulation, and official guidance for the specific medicine should be consulted.


Q: Is it okay to take Azitromicina Nifa with non-prescription pain relievers?

Official drug interaction lists primarily focus on prescription medicines. Common non-prescription pain relievers like acetaminophen or ibuprofen are generally not listed as contraindications, provided no other interacting conditions exist.


Q: Is Azitromicina Nifa effective against H. pylori infections?

Azitromicina Nifa is not typically indicated as the only medicine for H. pylori infections. However, some regulatory guidelines may describe its use as part of a specific multi-drug regimen to treat these types of infections.


Q: Does Azitromicina Nifa cause sun sensitivity?

Official adverse reaction documents list photosensitivity reactions (increased sensitivity to sunlight) as a potential, although uncommon, adverse effect. Patients are generally informed that precautions against sun exposure may be warranted during treatment.


Q: Why is Azitromicina Nifa sometimes referred to as a macrolide antibiotic?

Official documents classify Azithromycin as an azalide, which is a type of macrolide antibiotic. It is referred to this way because it shares the same basic structure and therapeutic mechanism of action as the macrolide class, binding to the bacterial 50S ribosomal subunit.


Q: Does Azitromicina Nifa contain lactose or gluten?

This information is specific to the manufacturer and formulation. Official Summary of Product Characteristics (SmPC) documents list all excipients, or inactive ingredients, including whether the specific tablet or capsule contains substances like lactose or gluten.


Q: Is a prescription always required to get Azitromicina Nifa?

In most jurisdictions regulated by bodies like the FDA or EMA, Azitromicina Nifa is legally classified as a prescription-only medicine (POM). This means it requires a valid prescription before it can be legally dispensed.


Q: What kind of monitoring is needed while taking Azitromicina Nifa?

Regulatory guidance recommends special monitoring for patients taking certain interacting drugs, such as Warfarin or Digoxin. Monitoring of liver function tests may also be required in patients with pre-existing liver issues or if symptoms of liver problems develop.


Q: Can Azitromicina Nifa interact with supplements or herbal remedies?

Official documents focus on interactions with prescription medicines but issue general warnings against co-administration with products that might affect heart rhythm or liver function. Patients are typically encouraged to disclose all co-administered substances to their prescriber.


Q: How is Azitromicina Nifa different from Erythromycin?

Azitromicina Nifa (Azithromycin) is chemically derived from Erythromycin, giving it different pharmacological properties. The main distinction is Azithromycin's significantly longer half-life, which enables a much shorter, once-daily course of treatment.


Q: Is it possible for Azitromicina Nifa not to work for my infection?

Yes. Regulatory documents stress that the medicine should only be used to treat infections strongly suspected to be caused by susceptible bacteria. Treatment failure can occur if the bacteria causing the infection are not susceptible or have developed resistance to macrolides.


Q: Does Azitromicina Nifa cause yeast infections?

Official adverse reaction reports include candidiasis (a type of yeast infection) as a potential side effect. This is understood as a consequence of the antibiotic disrupting the natural balance of microorganisms in the body.


Q: What are the signs that Azitromicina Nifa is starting to work?

The official measure of treatment success is the clinical resolution of the infection. The signs that it is working are generally a reduction in the symptoms associated with the infection, such as fever, pain, or inflammation.


Q: How long after the course can I expect to see all side effects disappear?

Because Azithromycin has a long half-life, it remains in the body for several days after the last dose, and side effects are generally expected to subside as the drug is cleared. Recovery time varies depending on the specific side effect and the individual.


Q: Why is Azitromicina Nifa used for certain sexually transmitted infections?

Official indications include its use for specific sexually transmitted bacterial infections, such as those caused by Chlamydia trachomatis. The drug’s ability to achieve high concentrations in tissues and its long half-life make it suitable for these short-course treatments.


Q: Can Azitromicina Nifa cause dizziness?

Yes, dizziness is officially listed as a common adverse reaction associated with the use of Azithromycin. Due to this potential effect, regulatory documents describe that caution may be warranted when performing tasks that require concentration.


Q: Is there a generic version of Azitromicina Nifa available?

Yes, regulatory drug databases confirm that the active ingredient, Azithromycin, is widely available from multiple manufacturers as a generic formulation. Generic medicines contain the same active ingredient and are subject to the same strict quality standards.


Q: Does Azitromicina Nifa have an effect on kidney function?

Official documents state that no dose adjustment is typically needed for patients with mild to moderate kidney problems. However, caution is officially advised for patients with severe renal impairment, and reports of rare cases of acute renal failure have been documented.

Advertisements

How should Azitromicina Nifa be stored and disposed of?

How to Store and Dispose of Azitromicina Nifa?

The storage and disposal instructions for Azitromicina Nifa (Azithromycin) are defined by the required product stability. The unmixed dry powder for oral suspension should generally be stored below 30 C in its original container.

Storage of Reconstituted Suspension

Once mixed with water, the resulting suspension must be used within 10 days. Store the liquid suspension at a controlled temperature between 5 to 30 C (41 to 86 F).

  • Handling: The suspension must be shaken well before each use, and the container should be kept tightly closed.
  • Disposal: Any unused portion of the liquid suspension must be discarded after the 10-day stability period has passed or immediately upon completion of the full prescribed course of treatment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azitromicina Nifa found in:

A-Z Index: